Pfizer FOIA Case

Pfizer FOIA Case

Pfizer FOIA Case

Re: the Legality of Pfizer taking 75 years to release the data on its covid vaccine

 

Back to All Cases

Facts of the Case

  • Dates: Jan 6, 2022
  • Location: USA
  • Court: US District Court for the Northern District of Texas, Fort Worth Div.
  • Case #: 4:21-cv-1058-P
  • Plaintiff: PHMPT, Plaintiff
  • Defendant: FDA
  • Trial Type: FOIA Request
  • Judge:
  • Status: Dedided
  • Verdict: for the Plaintiff


 

Background

The Firm of Attorney Aaron Siri, on behalf of Public Health and Medical Professionals for Transparency (PHMPT), and an unnamed client made a request : that the FDA produce all the data submitted by Pfizer to license its Covid-19 vaccine. [1]

The FDA asked the Court for permission to only be required to produce at a rate of 500 pages per month, which would have taken over 75 years to produce all the documents. [1]

 

This case involves the Freedom of Information Act (“FOIA”). Specifically, at issue is Plaintiff’s FOIA request seeking “[a]ll data and information for the Pfizer Vaccine enumerated in 21 C.F.R. § 601.51(e) with the exception of publicly available reports on the Vaccine Adverse Events Reporting System” from the Food and Drug Administration (“FDA”). See ECF No. 1. As has become standard, the Parties failed to agree to a mutually acceptable production schedule; instead, they submitted dueling production schedules for this Court’s consideration. Accordingly, the Court held a conference with the Parties to determine an appropriate production schedule.[1] See ECF Nos. 21, 34. [2]

 

Significance

According to Siri, this case about the importance of transparency and the excessive role of : government federal “health”  authorities have had on the data needed for independent scientists to offer solutions and address serious issues with the current vaccine program – issues which include waning immunity, variants evading vaccine immunity, and, as the CDC has confirmed, that the vaccines do not prevent transmission. [1]

 

Plaintiff’s Argument

The Plaintiff argued that the documents should be made public as it has a right to know what it has bought and paid for.  The issue is about transparency and the ability of scientists and everyone involved in the management of a crisis to have the best information available in order to serve the society as efficiently and usefully as possible. [1]

No person should ever be coerced to engage in an unwanted medical procedure. And while it is bad enough the government violated this basic liberty right by mandating the Covid-19 vaccine, the government also wanted to hide the data by waiting to fully produce what it relied upon to license this product until almost every American alive today is dead. That form of governance is destructive to liberty and antithetical to the openness required in a democratic society. [1]

 

Defendant’s Argument

…More information is needed…

 

Relevant Prior Judgements/ Cases

The Court order discussed the following cases: [2]

  • “[t]he basic purpose of FOIA is to ensure an informed citizenry, [which is] vital to the functioning of a democratic society.” NLRB v. Robbins Tire & Rubber Co., 437 U.S. 214, 242 (1977). “
  • FOIA was [therefore] enacted to ‘pierce the veil of administrative secrecy and to open agency action to the light of public scrutiny.’” Batton v. Evers, 598 F.3d 169, 175 (5th Cir. 2010) (quoting Dep’t of the Air Force v. Rose, 425 U.S. 352, 361 (1976)).
  • And “Congress has long recognized that ‘information is often useful only if it is timely’ and that, therefore ‘excessive delay by the agency in its response is often tantamount to denial.’” Open Soc’y Just. Initiative v. CIA, 399 F. Supp. 3d 161, 165 (S.D.N.Y. 2019) (quoting H.R. REP. NO. 93-876, at 6271 (1974)).
  • When needed, a court “may use its equitable powers to require an agency to process documents according to a court-imposed timeline.” Clemente v. FBI, 71 F. Supp. 3d 262, 269 (D.D.C. 2014).

 

Decision

A federal judge soundly rejected the FDA’s request and ordered the FDA to produce all the data at a clip of 55,000 pages per month! [1]

The Judge recognized that the release of this data is of paramount public importance and should be one of the FDA’s highest priorities. He then aptly quoted James Madison as saying a “popular Government, without popular information, or the means of acquiring it, is but a Prologue to a Farce or a Tragedy” and John F. Kennedy as explaining that a “nation that is afraid to let its people judge the truth and falsehood in an open market is a nation that is afraid of its people.” [1]

According to the order: [2]

“[t]he basic purpose of FOIA is to ensure an informed citizenry, [which is] vital to the functioning of a democratic society.” NLRB v. Robbins Tire & Rubber Co., 437 U.S. 214, 242 (1977). “FOIA was [therefore] enacted to ‘pierce the veil of administrative secrecy and to open agency action to the light of public scrutiny.’”
there may not be a “more important issue at the Food and Drug Administration . . . than the pandemic, the Pfizer vaccine, getting every American vaccinated, [and] making sure that the American public is assured that this was not [] rush[ed] on behalf of the United States . . . .” ECF No. 34 at 46. Accordingly, the Court concludes that this FOIA request is of paramount public importance. [2]
“[S]tale information is of little value.” Payne Enters., Inc. v. United States, 837 F.2d 486, 494 (D.C. Cir. 1988). The Court, agreeing with this truism, therefore concludes that the expeditious completion of Plaintiff’s request is not only practicable, but necessary.[2]
Accordingly, having considered the Parties’ arguments, filings in support, and the applicable law, the Court ORDERS that:
[2]

  1. The FDA shall produce the “more than 12,000 pages” articulated in its own proposal, see ECF No. 29 at 24, on or before January 31, 2022.
  2. The FDA shall produce the remaining documents at a rate of 55,000 pages every 30 days, with the first production being due on or before March 1, 2022, until production is complete.
  3. To the extent the FDA asserts any privilege, exemption, or exclusion as to any responsive record or portion thereof, FDA shall, concurrent with each production required by this Order, produce a redacted version of the record, redacting only those portions as to which privilege, exemption, or exclusion is asserted.
  4. The Parties shall submit a Joint Status Report detailing the progress of the rolling production by April 1, 2022, and every 90 days thereafter.

Aftermath

…More information is needed…

 


Further Research

Court Documents:
In the news:
  • …More information is needed…

other:

 

Media

……

source: ….

….

source: ….

 

References

  1. Court Orders FDA to Produce Pfizer Covid-19 Data at a rate of 500 pages per month
  2. The Judge’s Ruling / Order

 

Keyword

Aaron, Adverse reactions, CDC, Data, FOIA, Informed Citizenry, JFK, Kennedy, License, Madison, Pfizer, Secrecy, Siri, Transparency, Trial, usa, Vaccine, VAERS


Back to All Cases

 

Legal Opinion-Bahner-VaxLegality

Legal Opinion-Bahner-VaxLegality

Legal Opinion

Re: the illegal implementation of the vaccines & violation of German & EU Medical Laws

 

Back to All Cases

Legal Report written by the German lawyer Beate Bahner, outlining the many violations under German & EU Law of the Covid Inoculation program. (Dated Dec 27, 2021)

  • Section 1 : is the full original document (in German)
  • Section 2 : is a ‘Working English’ translation made by Corona Cases of item “9. Summary” of lawyer Bahner’s document

(i.e. it is not an ‘official translation’ authorized for legal purposes but only intended as an aid to understanding of the main content of the German summary.)

  • Section 3 : is a Video in which she warns of the Criminal Consequences of participating in the inoculation program (with English Subtitles).

1

Click the “View Fullscreen” button below to get full functionality in fullscreen.


2

9. Summary

1. A substance may only be used for the manufacture of a medicinal product if the intended use is either described in a monograph in accordance with the pharmacopoeia in a monograph, or extensive additional studies, including toxicity studies and clinical studies are submitted for the new new excipients. 

2. The sense and purpose of all German and European pharmaceutical regulations is the protection of people through the quality, safety and efficacy of medicinal products.

3. EMA [the European Medicines Agency] has imposed special conditions on BioNTech – particularly with regard to the two lipid nanoparticles, ALC 0315 and ALC 0159 in particular, as these are novel adjuvants for the Comirnaty vaccine and used for the first time on humans and in a novel way.

4. The corresponding special conditions of the EMA (specific obligations SO2, SO4, SO5) for these novel adjuvants had to be fulfilled by Biontech by July 2021.

5. Both the EMA report on the extension of the conditional marketing authorization in October 2021 as well as the safety data sheet of Pfizer for Comirnaty dated 7.12.2021 show that these conditions have not been fulfilled and that the required documentation is not available. It says: “No data available”. 

6. This is a violation of the principles of good manufacturing practice and thus also a a violation of the recognized pharmaceutical rules in the sense of § 8 para. 1 no. 1 AMG. According to this, it is forbidden to bring medicinal products into the market such that “by deviation from the recognized pharmaceutical rules, their quality is not insignificantly reduced”.

7. The quality is already reduced by the fact alone that two essential ingredients contained in Comirnaty are not intended for use in or on humans and are therefore considered “novel excipients” for which special documents and evidence must be provided.

8. In addition, lipid-related impurities in the vaccine are already documented in EMA’s registration dossier. Impurities of the vaccine are documented. These impurities are likely to increase in the light of further information on the reduction in filtration processes of the adjuvant nanolipid ALC-0315, these impurities may have even increased. With the reduction of the filtering processes, the marketing authorization holder would also violate S02, SO4 and SO5 of EMA in the marketing authorization notice.

9. Finally, according to the safety reports of the Paul Ehrlich Institute, the vaccine shows an alarming number of harmful effects that far beyond what is “justifiable” according to medical science.

10. Due to this fact, there is furthermore a violation of § 5 para. 1 AMG namely, a violation of the prohibition of the marketing and use of questionable medicinal products. Thus, not only the manufacturers but also the vaccinating physicians, as well as all persons responsible for a vaccination with Comirnaty are subject to the regulations of the Medicinal Products Act.

11. Violations of § 8 AMG and § 5 AMG are classified as criminal offenses according to § 95 para. 1 no. 1 and no. 3a and are punishable by up to 3 years’ imprisonment. Negligent commission is also punishable, § 95 para. 4 AMG.

12. A particularly serious case of this offense with imprisonment of up to 10 years if another person is exposed to the risk of death or serious injury to body or health, § 95 (3) No. 2 AMG. In this case is the manufacture, distribution and use of the vaccine Comirnaty contrary to the prohibitions of §§ 5 and 8 AMG. is intentionally realized.

13. Furthermore, vaccination may not be carried out in the case of allergies to a component of the vaccine. Therefore, all persons to be vaccinated must be tested in advance for a possible allergy to one of the components in order to exclude any contraindication to the vaccination.

14. Therefore, a person may not be vaccinated until he or she has been tested for tolerance to each of the components of the vaccine with respect to allergic compatibility and the tolerance to all components of the Comirnaty vaccine has been medically confirmed.

15. Until then, vaccination with the Comirnaty vaccine must be prohibited due to the possibility of a serious health hazard.

16. An infringement not only violates the aforementioned provisions of the Medicinal Products of the Medicines Act, but also other principles of general criminal law.

17. All statements also apply to the vaccine Spikevax from MODERNA!

Heidelberg, 27 December 2021

Beate Bahner[signed]


3

Source: shortXXvids


 

Keywords

Bahner, Beate Bahner, BioNTech, Cominarty, EMA, European Medicines Agency, germany, imprisonment, Legal Opinion, Pfizer, prison, punishment


Back to All Cases

 

Pfizer Nigeria Trovan Case

Pfizer Nigeria Trovan Case

Pfizer Nigeria Trovan Case

Re: the Legality of Pfizer’s procedures to trial & administer a new drug without consent that resulted in deaths & severe injury of children

 

Back to All Cases

Facts of the Case

aka: Rabi Abdullahi, et al. v. Pfizer, Inc., 562 F.3d (2d Cir. 2009)

  • Argued: July 12, 2007
  • Location: New York
  • Court: U.S. 2nd Circuit Court of Appeals – Southern District of New York
  • Citations #: 562 F.3d 163
  • Docket #: 05-4863
  • Plaintiff: Rabi Abdullahi, et al
  • Defendant: Pfizer
  • Trial Type:
  • Judges: Pooler, B.D. Parker & Wesley
  • Status: End
  • Verdict: For the Plaintiff
  • Decided: Jan 30, 2009


 

Background

The case involved Pfizer which conducted an unapproved, trial of its experimental antibiotic, Trovan on children in Nigeria. (1)

Plaintiffs-Appellants Rabi Abdullahi and other Nigerian children and their guardians sued Defendant-Appellee Pfizer, Inc. under the ATS (“the Abdullahi action”).

They alleged that Pfizer violated a customary international law norm prohibiting involuntary medical experimentation on humans when it tested an experimental antibiotic on children in Nigeria, including themselves, without their consent or knowledge. Plaintiffs-Appellants Ajudu Ismaila Adamu and others, also children and their guardians who were part of Pfizer’s Nigerian drug experiment, brought a similar action against Pfizer, alleging violations of the ATS, the Connecticut Unfair Trade Practices Act (“CUTPA”), and the Connecticut Products Liability Act (“CPLA”) (“the Adamu action”) (2)

The appellants allege that at that time, Pfizer, the world’s largest pharmaceutical corporation, sought to gain the approval of the U.S. Food and Drug Administration (“FDA”) for the use on children of its new antibiotic, Trovafloxacin Mesylate, marketed as “Trovan.” They contend that in April 1996, Pfizer, dispatched three of its American physicians to work with four Nigerian doctors to experiment with Trovan on children who were patients in Nigeria’s Infectious Disease Hospital (“IDH”) in Kano, Nigeria. Working in concert with Nigerian government officials, the team allegedly recruited two hundred sick children who sought treatment at the IDH and gave half of the children Trovan and the other half Ceftriaxone, an FDA-approved antibiotic the safety and efficacy of which was well-established. Appellants contend that Pfizer knew that Trovan had never previously been tested on children in the form being used and that animal tests showed that Trovan had life-threatening side effects, including joint disease, abnormal cartilage growth, liver damage, and a degenerative bone condition. Pfizer purportedly gave the children who were in the Ceftriaxone control group a deliberately low dose in order to misrepresent the effectiveness of Trovan in relation to Ceftriaxone. After approximately two weeks, Pfizer allegedly concluded the experiment and left without administering follow-up care. According to the appellants, the tests caused the deaths of eleven children, five of whom had taken Trovan and six of whom had taken the lowered dose of Ceftriaxone, and left many others blind, deaf, paralyzed, or brain-damaged. (2)

Appellants claim that Pfizer, working in partnership with the Nigerian government, failed to secure the informed consent of either the children or their guardians and specifically failed to disclose or explain the experimental nature of the study or the serious risks involved. Although the treatment protocol required the researchers to offer or read the subjects documents requesting and facilitating their informed consent, this was allegedly not done in *170 either English or the subjects’ native language of Hausa. The appellants also contend that Pfizer deviated from its treatment protocol by not alerting the children or their guardians to the side effects of Trovan or other risks of the experiment, not providing them with the option of choosing alternative treatment, and not informing them that the non-governmental organization Médecins Sans Frontières (Doctors Without Borders) was providing a conventional and effective treatment for bacterial meningitis, free of charge, at the same site.[2] (2)

The appellants allege that, in an effort to rapidly secure FDA approval, Pfizer hastily assembled its test protocol at its research headquarters in Groton, Connecticut, and requested and received permission to proceed from the Nigerian government in March 1996. At the time, Pfizer also claimed to have secured approval from an IDH ethics committee. Appellants allege, however, that the March 1996 approval letter was backdated by Nigerian officials working at the government hospital well after the experiments had taken place and that at the time the letter was purportedly written, the IDH had no ethics committee.[3] Appellants also contend that the experiments were condemned by doctors, including one on Pfizer’s staff at the time of the Kano trial. (2)

*    *    *                   *    *    *                   *    *    *                   *    *    *                    *    *    *

In 1998, the FDA approved Trovan for use on adult patients only.

After reports of liver failure in patients who took Trovan, its use in America was eventually restricted to adult emergency care.

In 1999, the European Union banned its use.

*    *    *                   *    *    *                   *    *    *                   *    *    *                    *    *    *

 

Starting in 2001 several suits were taken to Nigerian courts, but without success.

Since then, a tectonic change has altered the relevant political landscape. In May 2007, the state of Kano brought criminal charges and civil claims against Pfizer, seeking over $2 billion in damages and restitution.[4] Around the same time, the federal government of Nigeria sued Pfizer and several of its employees, seeking $7 billion in damages.[5] None of these cases seek compensation for the subjects of the tests, who are the appellants before this Court. Pfizer then notified this Court that in light of these recent developments, which it believed required further consideration by the district court, it would not seek affirmance on the basis of forum non conveniens. (2)

In their twin complaints, which total 628 paragraphs, Plaintiffs make only four allegations concerning the role of the Nigerian government in the Trovan experiments:

(1) in order for the FDA to authorize the export of Trovan, “Pfizer obtained the required letter of request from the Nigerian government”; (

2) the government “arrang[ed] for Pfizer’s accommodation in Kano”;

(3) the government acted “to silence Nigerian physicians critical of [Pfizer’s] test”; and

(4) the government “assign[ed] Nigerian physicians to assist in the project.”[18] Elsewhere in their complaints, Plaintiffs note in conclusory fashion that a Nigerian doctor did not publicly object to the Trovan study because it “seemed to have the backing of the Nigerian government.” (2)

 

Significance

This case is significant as it challenges the legality of informed consent and the notion that the pharmaceutical company Pfizer may or may not experiment on people even in a foreign nation. It is further significant that the court cited the Nuremberg Code as: “the universally accepted norm in customary international law regarding nonconsensual medical experimentation.” (2)

 

Plaintiff’s Argument

The appellants ground their claims in four sources of international law that categorically forbid medical experimentation on non-consenting human subjects: (1) the Nuremberg Code, which states as its first principle that “[t]he voluntary consent of the human subject is absolutely essential”; (2) the World Medical Association’s Declaration of Helsinki, which sets forth ethical principles to guide physicians world-wide and provides that human subjects should be volunteers and grant their informed consent to participate in research; (3) the guidelines authored by the Council for International Organizations of Medical Services (“CIOMS”), which require “the voluntary informed consent of [a] prospective subject”; and (4) Article 7 of the International Covenant on Civil and Political Rights (“ICCPR”), which provides that “no one shall be subjected without his free consent to medical or scientific experimentation.”[7] (2)

The district court found that “non-consensual medical experimentation violates the law of nations and, therefore, the laws of the United States” and cited the Nuremberg Code for support. (2)

The Defendants argued that the Nuremberg Code was relevant:

This history illustrates that from its origins with the trial of the Nazi doctors at Nuremburg through its evolution in international conventions, agreements, declarations, and domestic laws and regulations, the norm prohibiting nonconsensual medical experimentation on human subjects has become firmly embedded and has secured *184 universal acceptance in the community of nations. Unlike our dissenting colleague’s customary international law analysis, which essentially rests on the mistaken assumption that ratified international treaties are the only valid sources of customary international law for ATS purposes, see Dissent at 200-02, we reach this conclusion as a result of our review of the multiplicity of sources—including international conventions, whether general or particular, and international custom as identified through international agreements, declarations and a consistent pattern of action by national law-making authorities—that our precedent requires us to examine for the purpose of determining the existence of a norm of customary international law. Our dissenting colleague’s reasoning fails to engage the incompatibility of nonconsensual human testing with key sources of customary international law identified in Article 38 of the ICJ’s statute, most importantly international custom, as evidence of a general practice accepted as law, as well as the general principles of law recognized by civilized nations. See supra pp. 174-75. (2)

 

Defendant’s Argument

…More information is needed…

 

Related Previous Cases

The ruling cites the Nuremberg Code as an important precedent for the following reasons:

In August 1947, Military Tribunal 1, staffed by American judges and prosecutors and conducted under American procedural rules, see George J. Annas, The Nuremberg Code in U.S. Courts: Ethics versus Expediency, in The Nazi Doctors and the Nuremberg Code 201, 201 (George J. Annas & Michael A. Grodin eds., 1992), promulgated the Nuremberg Code as part of the tribunal’s final judgment against fifteen doctors who were found guilty of war crimes and crimes against humanity for conducting medical experiments without the subjects’ consent, Brandt, 2 Nuremberg Trials, at 181-82. Among the nonconsensual experiments that the tribunal cited as a basis for their convictions were the testing of drugs for immunization against malaria, epidemic jaundice, typhus, smallpox and cholera. Id. at 175-178. Seven of the convicted doctors were sentenced to death and the remaining eight were sentenced to varying terms of imprisonment. Id. at 298-300. The tribunal emphasized that (2)

[i]n every single instance appearing in the record, subjects were used who did not consent to the experiments; indeed, as to some of the experiments, it is not even contended by the defendants that the subjects occupied the status of volunteers. (2)

Id. at 183. The judgment concluded that “[m]anifestly human experiments under such conditions are contrary to the principles of the law of nations as they result from usages established among civilized *179 peoples, from the laws of humanity, and from the dictates of public conscience.” Id. (emphasis added and internal quotation marks omitted). The Code created as part of the tribunal’s judgment therefore emphasized as its first principle that “[t]he voluntary consent of the human subject is absolutely essential.” Id. at 181. (2)

The American tribunal’s conclusion that action that contravened the Code’s first principle constituted a crime against humanity is a lucid indication of the international legal significance of the prohibition on nonconsensual medical experimentation. As Justices of the Supreme Court have recognized, “[t]he medical trials at Nuremberg in 1947 deeply impressed upon the world that experimentation with unknowing human subjects is morally and legally unacceptable.United States v. Stanley, 483 U.S. 669, 687, 107 S. Ct. 3054, 97 L. Ed. 2d 550 (1987) (Brennan, J., concurring in part and dissenting in part) (emphasis added); see also id. at 709-10, 107 S. Ct. 3054 (O’Connor, J., concurring in part and dissenting in part). (2)

Moreover, both the legal principles articulated in the trials’ authorizing documents and their application in judgments at Nuremberg occupy a position of special importance in the development of bedrock norms of international law. United States courts examining the Nuremberg judgments have recognized that “[t]he universal and fundamental rights of human beings identified by Nuremberg—rights against genocide, enslavement, and other inhumane acts …—are the direct ancestors of the universal and fundamental norms recognized as jus cogens,” from which no derogation is permitted, irrespective of the consent or practice of a given State. Siderman de Blake v. Republic of Arg., 965 F.2d 699, 715 (9th Cir.1992) (cited in Sampson v. F.R.G., 250 F.3d 1145, 1150 (7th Cir.2001)). As Telford Taylor, who first served as an assistant to Justice Robert Jackson during his time as Chief Prosecutor for the IMT and then became Chief of Counsel for War Crimes on the Nuremberg trials held under the authority of Control Council Law No. 10, explained, “Nuremberg was based on enduring [legal] principles and not on temporary political expedients, and this fundamental point is apparent from the reaffirmation of the Nuernberg principles in Control Council Law No. 10, and their application and refinement in the 12 judgments rendered under that law during the 3-year period, 1947 to 1949.” Taylor, Report on Nuernberg War Crimes Trials, at 107 (emphasis added). (2)

  •  

Additional international law sources support the norm’s status as customary international law.

  • The European Union embraced the norm prohibiting nonconsensual medical experimentation through a 2001 Directive passed by the European Parliament and the Council of the European Union. The Directive accepted the informed consent principles of the 1996 version of the Declaration of Helsinki. Council Directive 2001/20/EC, preamble (2), 2001 O.J. (L 121) 37(EC) [hereinafter 2001 Clinical Trial Directive]. It also required member States to adopt rules protecting individuals incapable of giving informed consent and permitting clinical trials only where “the trial subject or, when the person is not able to give informed consent, his legal representative has given his written consent after being informed of the nature, significance, implications and risks of the clinical trial.Id. at art. (1), (2)(d). The Directive further required all member States to implement by 2004 domestic laws, regulations, and administrative provisions to comply with its informed consent requirements. Id. at art. 22(1). (2)
  • Since 1997, thirty-four member States of the Council of Europe have also signed the Convention on Human Rights and Biomedicine, a binding convention and a source of customary international law. (2)
  • In 2005, the General Conference of the United Nations Educational, Scientific and Cultural Organization (UNESCO) adopted the Universal Declaration on Bioethics and Human Rights, which requires “the prior, free, express and informed consent of the person concerned” for research-oriented treatments. Universal Declaration on Bioethics and Human Rights, UNESCO Gen. Conf. Res., at art. 6, 33rd Sess., 33 C/Resolution 36, (Oct. 19, 2005). (2)

 

Decision

The court ruled to ” REVERSE the judgments of the district court and REMAND for further proceedings.”
 
Regarding the Nuremberg Code it said “The Nuremberg trials are unquestionably one of this country’s greatest and most enduring contributions to the field of international law.” (2)

 

Aftermath

Pfizer agreed to pay 75 million dollars in damages if the plaintiffs take DNS tests. Many refused as they did not trust Pfizer with further “medical” procedures.

 

Further Research

Court Documents:
In the news:
  • …More information is needed…

 

Media

Pfizer’s Trovan Trial & Settlement

source: Al Jazeera English

Pfizer Criminal case adjourned until October 2015

source: AP Archive

Pfizer Criminal History

source: Odysee

 

References

  1. The Significance of the Nuremberg Code
  2. Court Ruling

 

Keyword

Pfizer, Informed Consent, Trovan, Nigeria, Nuremberg, Court of Appeals, USA


Back to All Cases